EVQLV’s very own Andrew Satz (CEO and CO-Founder) was a guest on the M2 Techcast of MITechNews.com with Mike Brennan and Matt Roush. He discussed our work on coronavirus, what is and isn’t artificial intelligence, the application of AI, and our mission at EVQLV.
We’re not sharing this information to scare, but instead to inform on the challenges the healthcare industry is facing. With that in mind, below we report on 21 innovative efforts from leading and emerging players in the biotech industry to combat the COVID-19 pandemic.
BioIDEA and EVQLV are hosting a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
The World Health Organization (WHO), yesterday, released a public statement for collaboration on COVID-19 treatment development of which Andrew Satz (CEO, EVQLV) gladly joined his name.
Edward Turner of TMR Blog recently covered our work on COVID-19. He did a nice job summarizing the potential efficacy of our algorithm in an understandable and digestible manner, while including EVQLV’s optimism on the project.
EVQLV, has submitted their first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2. These DNA sequences were generated using computational antibody design, a method which combines mathematics, statistics, and computer science to identify high-affinity antibodies.
In the AI vs COVID-19 battle there are three major areas where breakthroughs are needed, coming and have arrived: diagnosis, treatment and epidemiology. In this post, we focus on five companies who are using epidemiology to aid researchers and the general public in the fight against COVID-19.
Brett Averso, CTO, and I recently had a follow up discussion on our first coronavirus chat. Brett provided visualizations and commentary on coronavirus (SARS-CoV-2), ACE2, SARS-CoV-2 with SARS overlay, and antibody fragments to help people better understand the threat we’re currently facing, as well as put it in its proper context. Brett also discussed the role AI can play in finding an effective treatment for COVID-19.
Brett Averso, CTO, and I linked up to discuss the coronavirus (SARS-CoV-2). Brett covered what exactly the coronavirus is, the threat it currently presents, how we can best protect ourselves and our loved ones against infection, and what EVQLV is doing to address the outbreak.
Talem Therapeutics, a subsidiary of ImmunoPrecise, and EVQLV announced a new collaboration aimed at accelerating the global effort to develop lead therapeutic and vaccine candidates against the SARS-CoV-2 virus (coronavirus).